A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of HRS-1893 in Healthy Participants
Latest Information Update: 07 Jul 2025
At a glance
- Drugs HRS-1893 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Atridia
Most Recent Events
- 29 Jun 2025 Status changed from not yet recruiting to recruiting.
- 27 Jun 2025 New trial record